

Consolidated Financial Statements

For the Years Ended December 31, 2020 and 2019

Presented in Canadian Dollars



April 30, 2021

MANAGEMENT'S RESPONSIBILITY FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The accompanying consolidated financial statements of Fountain Asset Corp. (the "**Company**") were prepared by management in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Management acknowledges responsibility for the preparation and presentation of the consolidated financial statements, including responsibility for significant accounting judgments and estimates and the choice of accounting principles and methods that are appropriate to the Company's circumstances. The Company's significant accounting policies are summarized in note 2 to the consolidated financial statements.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors is responsible for reviewing and approving the consolidated financial statements and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the internal controls over the financial reporting process, the consolidated financial statements and the auditors' report. The Audit Committee also reviews the Company's Management's Discussion and Analysis to ensure that the financial information reported therein is consistent with the information presented in the consolidated financial statements. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the consolidated financial statements for issuance to shareholders.

Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

(Signed) "Andrew Parks" Andrew Parks President & Chief Executive Officer (Signed) *"Michael Leskovec"* Michael Leskovec Chief Financial Officer



To the Shareholders of Fountain Asset Corp.:

Opinion

We have audited the consolidated financial statements of Fountain Asset Corp. and its subsidiaries (the "Company"), which comprise the consolidated statements of financial position as at December 31, 2020 and December 31, 2019, and the consolidated statements of income (loss) and comprehensive income (loss), changes in shareholders' equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at December 31, 2020 and December 31, 2019, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with International Financial Reporting Standards.

Basis for Opinion

We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audits of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. The other information comprises Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audits of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audits or otherwise appears to be materially misstated. We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud
 or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient
 and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from
 fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions,
 misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audits and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Marufur Raza.

MNPLLP

Toronto, Ontario April 30, 2021 Chartered Professional Accountants Licensed Public Accountants



| FOUNTA | IN ASSET |
|--------|----------|
| | |

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Presented in Canadian Dollars

| As at December 31, | | 2020 | 2019 |
|---|----|--------------|---------------|
| ASSETS | | | |
| Cash | \$ | 1,022,934 | \$ 335,537 |
| Short-term investments (note 4) | | 40,000 | 40,000 |
| Amounts receivable and sundry assets | | 1,234,233 | 625,945 |
| Loans and convertible debentures - fair value through profit or loss (note 5) | | 1,299,195 | 2,985,562 |
| Investments - fair value through profit or loss (note 6) | | 15,993,398 | 14,406,297 |
| | \$ | 19,589,760 | \$ 18,393,341 |
| LIABILITIES | | | |
| Accounts payable and accrued liabilities | \$ | 303,103 | \$ 398,095 |
| Accrued annual incentive plan (note 11) | • | - | 2,085,394 |
| Income taxes payable (note 14) | | 29,375 | 29,375 |
| | | 332,478 | 2,512,864 |
| SHAREHOLDERS' EQUITY | | | |
| Share capital (note 9(b)) | | 29,799,107 | 29,153,357 |
| Contributed surplus (note 9(c)) | | 6,524,036 | 6,369,593 |
| Deficit | | (17,065,861) | (19,642,473) |
| | | 19,257,282 | 15,880,477 |
| | \$ | 19,589,760 | \$ 18,393,341 |

Contingencies and commitments (note 16)

The accompanying notes are an integral part of the consolidated financial statements

On behalf of the Board:

(Signed) "Andrew Parks" Director

(Signed) "Morris Prychidny" Director



CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)

| For the years ended December 31, | 2020 | 2019 |
|--|--------------------------|----------------|
| Revenue | | |
| Net unrealized gains (losses) on portfolio investments | \$ 11,026,376 | \$ (17,043,178 |
| Structuring fees, consulting fees and bonuses | 578,273 | 878,805 |
| Interest and dividend income | 175,919 | 326,150 |
| Net realized losses on portfolio investments | (9,054,146) | (1,332,308 |
| | 2,726,422 | (17,170,531 |
| Expenses | | |
| Salaries and consulting fees | 304,953 | 340,093 |
| Audit and legal fees | 280,665 | 256,505 |
| General and administrative | 297,820 | 262,494 |
| Commissions | 76,385 | 119,642 |
| Filing and listing fees | 28,232 | 10,105 |
| Stock-based compensation (note 9(c)) | 154,443 | 316,366 |
| Foreign exchange loss | 72,068 | - |
| Gain on debt settlement | (1,064,756) | - |
| | 149,810 | 1,305,205 |
| Income (loss) before income taxes | 2,576,612 | (18,475,736 |
| Income tax provision (note 14) | - | (29,375 |
| Net income (loss) and comprehensive income (loss) | \$ 2,576,612 | \$ (18,505,111 |
| Net income (loss) per share - basic and diluted | \$ 0.04 | \$ (0.31 |
| Weighted everyone number of charge outstanding during the veryon | | |
| Weighted average number of shares outstanding during the years: Basic | 59,002,304 | 58,994,462 |
| Diluted | 59,002,304 59,021,812 | 58,994,462 |

The accompanying notes are an integral part of the consolidated financial statements



CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

Presented in Canadian Dollars

| | Share Capital | Contributed surplus | Deficit | Total shareholders' equity |
|---|------------------|---------------------|-----------------|----------------------------------|
| Balance at December 31, 2018 | \$ 29,153,357 \$ | 6,053,227 \$ | (1,137,362) \$ | 34,069,222 |
| Stock based compensation | - | 316,366 | - | 316,366 |
| Comprehensive loss | - | - | (18,505,111) | (18,505,111) |
| Balance at December 31, 2019 | 29,153,357 | 6,369,593 | (19,642,473) | 15,880,477 |
| Stock based compensation | - | 154,443 | - | 154,443 |
| Issuance of common shares on settlement of debt | 645,750 | - | - | 645,750 |
| Comprehensive loss | <u> </u> | - | 2,576,612 | 2,576,612 |
| Balance at December 31, 2020 | \$ 29,799,107 \$ | 6,524,036 \$ | (17,065,861) \$ | 19,257,282 |

The accompanying notes are an integral part of the consolidated financial statements



CONSOLIDATED STATEMENTS OF CASH FLOWS

Presented in Canadian Dollars

| For the years ended December 31, | 2020 | 2019 |
|--|-------------------------------|-----------------|
| Cash provided by (used in) | | |
| Operations | | |
| Net income (loss) | \$ 2,576,612 | \$ (18,505,111) |
| Items not involving cash: | | (· · ·) |
| Income tax provision | - | 29,375 |
| Unrealized losses (gains) on portfolio investments | (11,026,376) | 17,043,178 |
| Realized losses on sale of portfolio investments | | 1,332,308 |
| Proceeds from sale of investments | | 14,697,673 |
| Purchase of investments | (4,589,347) | |
| Acquired loans and convertible debentures | - · · · · | (4,113,376) |
| Repayments of loans and convertible debentures | - | 3,639,575 |
| Gain on debt settlement | (1,064,756) | - |
| Structuring fees | (578,273) | - |
| Stock compensation expense | `154 ,443 [´] | 316,366 |
| Change in non-cash working capital: | | , |
| Amounts receivable and sundry assets | (608,288) | 23,981 |
| Accounts payable and accrued liabilities | `(94,992) | 136,497 |
| Accrued annual incentive plan | (374,885) | (500,000) |
| Change in cash | 687,397 | (1,078,655) |
| Cash beginning of year | 335,537 | 1,414,192 |
| Cash end of year | \$ 1,022,934 | \$ 335,537 |

Supplementary cash flow information (note 10)

The accompanying notes are an integral part of the consolidated financial statements



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

1. NATURE OF OPERATIONS

Fountain Asset Corp. (the **"Company**") is a publicly traded company incorporated and domiciled in Canada. The Company is an investment company focused on creating shareholder value by offering various debt and/or equity financing solutions to companies across many industries such as manufacturing, retail, financial services, technology, cannabis, biotechnology, oil and gas, mining, and cryptocurrency. The Company's subordinate voting shares are listed on the TSX Venture Exchange (**"TSXV**") under the symbol "FA".

The address of the Company's registered head office is 3 Market Street, Unit 609, Toronto, Ontario, M5E 0A3.

In March 2020, the World Health Organization declared a global pandemic related to the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19". This has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures which include the implementation of travel bans, self-imposed quarantine periods, and social distancing have caused material disruption to businesses resulting in a global economic disruption. At the same time, global equity markets have experienced historic volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize domestic economic conditions. The duration and eventual impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions.

The Corporation's ability to operate has not been directly impacted by the COVID-19 pandemic or the closure of nonessential businesses, but many of the Corporation's investee companies could be negatively impacted by the COVID-19 pandemic.

The audited consolidated financial statements as at and for the year ended December 31, 2020 have been approved for issue by the Board of Directors on April 27, 2021.

2. SIGNIFICANT ACCOUNTING POLICIES

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These financial statements have been prepared in accordance with accounting policies based on the IFRS standards and International Financial Reporting Interpretations Committee ("IFRIC") interpretations and have been consistently applied to all the years presented and by all subsidiaries. The principal accounting policies applied in the preparation of these financial statements are set out below.

These consolidated financial statements comprise the consolidated statements of income and statements of comprehensive income showing as two statements, the consolidated statements of financial position, the consolidated statement of changes in shareholders' equity, the consolidated statements of cash flows and the accompanying notes to the consolidated financial statements.

(b) Basis of presentation

These consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for valuation of fair value through profit or loss ("**FVTPL**") financial assets and financial liabilities which are shown at fair value. In addition, these financial statements have been prepared using the accrual basis of accounting except for cash flow information.

The Company classifies its expenses by function.

The consolidated statements of cash flows shows the changes in cash and cash equivalents arising during the year from operating activities, investing activities and financing activities.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

(b) Basis of presentation (continued)

The cash flows from operating activities are determined using the indirect method. Net income is therefore adjusted for non-cash items, such as measurement gains or losses, changes in provisions, as well as changes from receivables, prepaid expenses, accounts payable and accrued liabilities and income taxes receivable and payable. In addition, all income and expenses from cash transactions that are attributable to investing or financing activities are eliminated. Interest received or paid is classified as operating cash flows. The cash flows from investing and financing activities are determined using the direct method. The Company's assignment to operating, investing and financing category depends on the business model (management approach).

(c) Principles of consolidation

(i) Subsidiaries

A subsidiary is an entity over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. As an investment entity, the Company is required to account for its investments in subsidiaries (Somersby Park 2010 Limited Partnership, and the Auto repair finance company) at fair value through profit or loss rather than by consolidation.

The Company has concluded that Fountain Advisors Corp., Foothills Development Inc. ("**Foothills**"), and Foothills wholly-owned subsidiary Newborn Realty Corporation, should be consolidated as this entity provides services relating to the Company's investment activities. All intercompany balances, profits and transactions are eliminated in full. Foothills and Newborn were dissolved effective December 30, 2019 (note 7).

(ii) Status as investment entity

The following are the criteria within IFRS 10, Consolidated financial statements, which the Company used to evaluate and determine that it continues to meet the definition of an Investment Entity:

(a) Obtain funds from one or more investors for the purpose of providing those investor(s) with investment management services;

(b) Commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and

(c) Measures and evaluates the performance of substantially all its investments on a fair value basis.

The Company has evaluated the above criteria and determined that it meets the definition of an Investment Entity. As a result of meeting the definition of an Investment Entity, except for Foothills, subsidiaries which otherwise would have been consolidated are carried at fair value.

(d) Financial instruments

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the financial instrument. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e. the date that the Company commits to purchase or sale of the asset. Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognized when it is extinguished, discharged, cancelled or when it expires.

All new investments held by the Company are designated as FVTPL upon initial recognition. The Company includes equities, loans and receivables, and other interest-bearing investments in this category. These financial assets and liabilities are designated upon initial recognition on the basis that they are part of a group of financial instruments that are managed and have their performance evaluated on a fair value basis, in accordance with risk management and investment strategies of the Company.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

(d) Financial instruments (continued)

(i) Financial assets

The Company recognizes financial assets when it becomes party to the contractual provisions of the instrument. Financial assets are measured initially at their fair value plus, in the case of financial assets not subsequently measured at FVTPL, transaction costs that are directly attributable to their acquisition. Transaction costs attributable to the acquisition of financial assets subsequently measured at FVTPL are expensed in profit or loss when incurred. The Company derecognizes financial assets when its contractual rights to the cashflows from the financial asset expire.

On initial recognition, financial assets are classified as subsequently measured at amortized cost, fair value through other comprehensive income ("**FVOCI**") or FVTPL. The Company determines the classification of its financial assets, together with any embedded derivatives, based on the business model for managing the financial assets and their contractual cash flow characteristics.

Financial assets are classified into one of following categories: FVTPL, loans and receivables and available for sale.

| | Classification | Measurement |
|---------------------------------------|----------------|----------------|
| Cash | FVTPL | Fair value |
| Accounts Receivable and sundry assets | Amortized cost | Amortized cost |
| Investments | FVTPL | Fair value |
| Short-term investments | FVTPL | Fair value |
| Loans and convertible debentures | FVTPL | Fair value |

The Company does not have financial assets classified as FVOCI.

Business model assessment

The Company assesses the objective of its business model for holding a financial asset at a level of aggregation which best reflects the way the business is managed, and information is provided to management. Information considered in this assessment includes stated policies and objectives.

Contractual cash flow assessment

The cash flows of financial assets are assessed as to whether they are solely payments of principal and interest on the basis of their contractual terms. For this purpose, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money, the credit risk associated with the principal amount outstanding, and other basic lending risks and costs. In performing this assessment, the Company considers factors that would alter the timing and amount of cash flows such as prepayment and extension features, terms that might limit the Company's claim to cash flows, and any features that modify consideration for the time value of money.

All financial instruments are measured at fair value except for loans and receivables which are measured at amortized cost, using the effective interest method where applicable. Subsequent measurement and changes in fair value will depend on their initial classification, as follows: FVTPL financial assets are measured at fair value and changes in fair value are recognized in net income.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

(d) Financial instruments (continued)

Cash, Short-Term Investments, Derivatives and Conversion Features of Convertible Debt:

Cash, short-term investments, derivatives and conversion features of convertible debt are classified as FVTPL. Cash and cash equivalents consists of cash on hand and short-term investments with remaining maturities of less than three months.

Loans and Receivables:

Accounts receivables are designated as loans and receivables which are measured at amortized cost, subject to impairment reviews.

Convertible Debenture Receivable:

When the Company holds debentures that are convertible into the issuer's equity shares at the Company's option, the equity conversion feature represents an embedded option written by the issuer on its equity shares. The convertible debenture is classified as FVTPL and recorded at fair value.

Investments in Publicly Traded Companies:

Investments in publicly traded companies have been designated as FVTPL and are recorded in the consolidated statements of financial position at fair value. Fair value is determined directly by reference to quoted market closing prices in active markets. In instances where securities are subject to restrictions on sale or transfer, the securities are recorded at amounts discounted from market value to a maximum of 20%. In determining the discount for such investments, the Company considers the nature and length of the restriction.

Included in investments is the fair value of the Company's investments in share purchase warrants and options of other corporations which are designated at FVTPL. Where the value of these warrants and options is not publicly quoted in active markets, the Company employs the Black-Scholes pricing model to determine fair value.

Investments in Private Companies:

Privately-held investments have been designated as fair value through profit or loss and are recorded in the consolidated statements of financial position at fair value. Fair value is measured using one or more of the valuation indicators described below. These are included in level 2 or 3 of the fair value hierarchy. The determinations of fair value of the Company's privately-held investments are subject to certain limitations.

(ii) Financial liabilities

Financial liabilities are classified into one of two categories: FVTPL or other financial liabilities.

Accounts payable and accrued liabilities, and the accrued annual incentive plan are classified as other financial liabilities which are measured at amortized cost. Syndicated debt is designated as FVTPL, as the Company's investment portfolio is evaluated on a fair value basis.

(e) Financial instruments recorded at fair value

Financial instruments recorded at fair value on the statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

(e) Financial instruments recorded at fair value (continued)

- Level 1 Valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 Valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 Valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Publicly traded marketable securities and other investments, including shares, options and warrants are recorded at fair values based on the last quoted close price, within the bid-ask spread, at the statement of financial position date. For options and warrants which are not traded on a recognized securities exchange and where there are sufficient and reliable observable market inputs, the Black-Scholes model for valuation is used.

Private investments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured and options and warrants that are linked to and must be settled by delivery of unquoted equity investments are recorded at cost, which is the fair value at the time of acquisition.

(f) Impairment

The Company recognizes a loss allowance for the expected credit losses associated with its financial assets, other than financial assets measured at fair value through profit or loss. Expected credit losses are measured to reflect a probability-weighted amount, the time value of money, and reasonable and supportable information regarding past events, current conditions and forecasts of future economic conditions.

The Company applies the simplified approach for trade receivables. Using the simplified approach, the Company records a loss allowance equal to the expected credit losses resulting from all possible default events over the assets' contractual lifetime.

The Company assesses whether a financial asset is credit-impaired at the reporting date. Regular indicators that a financial instrument is credit-impaired include significant financial difficulties as evidenced through borrowing patterns or observed balances in other accounts and breaches of borrowing contracts such as default events or breaches of borrowing covenants. For financial assets assessed as credit-impaired at the reporting date, the Company continues to recognize a loss allowance equal to lifetime expected credit losses.

For financial assets measured at amortized cost, loss allowances for expected credit losses are presented in the statement of financial position as a deduction from the gross carrying amount of the financial asset.

Financial assets are written off when the Company has no reasonable expectations of recovering all or any portion thereof.

Should the cash flow assumptions used to determine the original loan loss provision change, the loan loss provision may be reversed. A loan loss provision is reversed only to the extent that the revised carrying value of the loan does not exceed its amortized cost that would have been recorded had no loan loss provision been recognized.

(g) Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

(h) Investments in associates

The Company has determined that it meets the definition of an "investment entity" and as a result, associates are measured at FVTPL. Refer to Note 8 for specific disclosures related to investments in associates.

(i) Revenue recognition

Interest income is recorded on an accrual basis using the effective interest method. Under the effective interest method, the interest rate realized is not necessarily the same as the stated loan interest rate. When a loan is classified as impaired, the original expected timing and amount of future cash flows may be revised to reflect new circumstances. These revised cash flows are discounted using the original effective interest rate to determine the impaired carrying value of the loan. Interest income is thereafter recognized on this impaired carrying value using the original effective interest rate. Additional changes to the amount or timing of future cash flows could result in further loan losses, or the reversal of prior loan losses, which would also impact the amount of subsequent interest income recognized. Interest and fees collected in advance are recorded as deferred revenue and recognized in income. Loan commitment, origination, structuring fees and bonuses are recorded as income over the life of the loan.

Purchases and sales of investments are recognized on the trade date. Realized gains and losses on disposal of investments and unrealized gains and losses in the value of investments are reflected in the consolidated statements of income (loss) and comprehensive income (loss). Realized losses may arise even if the investment is not disposed of in circumstances where the investee is insolvent.

Upon disposal of an investment, previously recognized unrealized gains or losses are reversed to recognize the full realized gain or loss in the period of disposition. All transaction costs associated with the acquisition and disposition of investments are expensed to the consolidated statements of income (loss) and comprehensive income (loss) as incurred.

Dividend income is recorded on the ex-dividend date and when the right to receive the dividend has been established. Other income and income from securities lending are recorded on an accrual basis.

Management and consulting fees are recognized over the period in which the services are provided.

(j) Foreign currencies

The financial statements are presented in Canadian dollars, which is the Company's functional currency. Transactions in currencies other than the functional currency are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at the period end exchange rates are recognized in the consolidated statements of income and comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

(k) Cash

Cash includes cash on hand and balances with brokers.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

(I) Income taxes

Income tax on the profit or loss for the periods presented comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is provided using the statement of financial position liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the financial position reporting date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

(m) Share based payment transactions

The fair value of share options granted to employees are recognized as an expense over the vesting period with a corresponding increase in equity. An individual is classified as an employee when the individual is an employee for legal or tax purposes (direct employee) or provides services similar to those performed by a direct employee, including Directors of the Company.

The fair value is measured at grant date and recognized over the period during which the options vest. The fair value of the options granted is measured using the Black-Scholes option pricing model, taking into account the terms and conditions upon which the options were granted. At each financial position reporting date, the amount recognized as an expense is adjusted to reflect the actual number of share options that are expected to vest.

(n) Earnings per share

Basic earnings per share are calculated using the weighted average number of multiple and subordinate voting shares outstanding during the year.

Diluted earnings per share is calculated by dividing net earnings available to shareholders for the period by the diluted weighted average number of multiple and subordinate shares outstanding during the period. The diluted weighted average number of shares includes the potential dilution from shares issuable through stock options, if dilutive. This assumes that the proceeds from any shares issued on the exercise of stock options are used by the Company to repurchase and cancel shares at the average market price of the Company's share price for the period. As such, where the strike price of stock options exceeds the average market price of the Company's shares for the reporting period, the inclusion of these shares under the treasury stock method would be anti-dilutive, so these shares are excluded from the calculation of the weighted average number of diluted shares outstanding.

In years that the Company reports a net loss, loss per share is not presented on a diluted basis, as the result would be anti-dilutive.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

3. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of these financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual outcomes could differ from these estimates. These financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

(a) Critical accounting estimates

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position reporting date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

- Valuation of deferred income tax assets The valuation of deferred income tax assets requires judgment on their recoverability. Such judgments are made based on management's estimate on the timing and amount of the Company's future taxable earnings; and
- (ii) Valuation methodology of level 2 and level 3 investments. Refer to note 8 for more details.

(b) Critical accounting judgments

Management exercises judgment in applying criteria in IFRS 10, which determines the Company's status as an investment entity. The determination of categories of financial assets and financial liabilities has been identified as an accounting policy choice which involves judgments or assessments made by management.

4. SHORT-TERM INVESTMENTS

The Company has outstanding \$40,000 in a short-term guaranteed investment certificate with its financial institution at December 31, 2020 (December 31, 2019 - \$40,000). These investments are held as security on its credit card line with a Schedule A Canadian chartered bank.

5. LOANS AND OTHER CONVERTIBLE DEBENTURES

| | | Interest rate / | instrument | Dec. 31, | 2019 | Dec. 31, | 2020 |
|---------------------------|------------------|-------------------|------------|--------------------|--------------|--------------|------------|
| FVTPL | Instrument | term | hierarchy | Cost | Fair value | Cost | Fair value |
| 2400918 Ontario Inc. | Term debt | 15%, < 1 year | Level 3 | \$ 3,024,129 | \$ | - | |
| Advantagewon Oil Corp. | Convertible debt | 24% & 12%, > 1 yr | Level 2 | 48,611 | | 50,096 | |
| Central Coast | Convertible debt | 8%, > 1 year | Level 3 | 268,040 | | - | |
| Compression Capital Corp. | Convertible debt | 5%, > 1 year | Level 3 | 500,000 | | 500,000 | |
| Cool Holdings Ltd. | Convertible debt | 12%, < 1 year | Level 2 | 786,267 | | - | |
| Cura Partners | Convertible debt | 8%, > 1 year | Level 3 | 327,611 | | - | |
| Humble & Fume Inc. | Convertible debt | 8%, > 1 year | Level 3 | 300,000 | | 300,000 | |
| Popreach Incorporated | Convertible debt | 8%, > 1 year | Level 3 | 250,000 | | - | |
| Rise Life Sciences | Convertible debt | 12%, > 1 year | Level 2 | 250,000 | | 250,000 | |
| Wayland Group Corp. | Convertible debt | 9%, > 1 year | Level 3 | 250,000 | | - | |
| Ways Security Inc. | Convertible debt | 6%, < 1 year | Level 3 | 62,095 | | 50,000 | |
| Cryptologic Corp. | Convertible debt | 8%, > 1 year | Level 2 | 568,598 | | - | |
| | | | | \$ 6,635,351 \$ | 2,985,562 \$ | 1,150,096 \$ | 1,299,1 |



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

6. INVESTMENTS - FVTPL

The following chart lists the investments carried at FVTPL. See note 8 for fair value measurement techniques and evaluations.

| 1616 Media Ltd. Equity 3 \$ 32,200 \$ 32,200 1014379 BC Limited Equity 3 - 7,500 245910 Onlando Equity 3 - 7,500 245910 Onlando Inc. Equity 3 21,227 211,227 Artican Camable Corp. Equity 3 450,000 440,000 Apriface Convoling Systems Ltd. Equity 3 176,008 176,008 413,000 Apriface Convoling Systems Ltd. Warants 3 81,442 81,442 81,442 Attorneys Title Guaranty Fund Inc. Equity 3 306,255 308,525 BabelSark Inc. Equity 3 202,565 202,565 202,565 Brazi Investments Inc. Equity 3 199,800 198,800 CannAgri Blockchain Inc. Warants 360,151 60,151 CannA | | | Financial instr. | Dec. 31, 2 | 019 | Dec. 31, 20 | 20 |
|---|---------------------------------------|------------|------------------|---------------------|---------------|--------------|------------|
| 1014379 BC Limited Equity 3 - 7.500 2459160 Ontario Inc. Equity 3 217.763 217.763 2459160 Ontario Inc. Equity 3 410.000 450.000 African Converging Systems Ltd. Equity 3 450.000 450.000 Apriface Converging Systems Ltd. Equity 3 413.000 413.000 BabelBark Inc. Equity 3 420.020 413.000 BabelBark Inc. Equity 3 202.665 202.265 BabelBark Inc. Equity 3 202.665 202.265 Brazil Investments Inc. Equity 3 202.665 202.265 Brazil Investments Inc. Equity 3 198.800 198.800 CannAgri Blockchain Inc. Equity 3 100.700 - Canthore Phoremaceuticals Corp. Equity 3 100.700 - Canthore Phoremaceuticals Corp. Equity 3 55.000 - Canthore Phoremaceuticals Corp. Equity 3 55.000 - Canthore Phoremaceuticals Corp. | Investment | Instrument | hierarchy | Cost | Fair value | Cost | Fair value |
| 126280 BC Ltd. Equity 3 - 30,000 2459160 Ontario Inc. Warrunts 3 112,237 112,237 Atcian Cannabis Corp. Equity 3 176,008 | 1616 Media Ltd. | Equity | 3 | \$ 32,920 | \$ | 32,920 | |
| 2459160 Ditario Inc. Equity 3 217.783 217.783 African Convanits Corp. Equity 3 450.000 450.000 Apriforce Growing Systems Ltd. Equity 3 176.008 177.008 Apriforce Growing Systems Ltd. Warrants 3 81.492 81.492 Attorneys Tille Guaranty Fund Inc. Equity 3 729.618 729.618 BabelBark Inc. Equity 3 300.855 400.855 Bravio Technologies Limited Equity 3 306.525 306.525 Bravio Technologies Limited Equity 3 305.479 305.479 CannAgri Blockchain Inc. Equity 3 110.849 110.849 CannAgri Blockchain Inc. Equity 3 190.700 - Cansters Holdings Inc. Equity 3 190.700 - Canster Marmaceulicais Corp. Equity 3 190.700 - Canster Holdings Inc. Equity 3 190.700 - CannAgri Blockchain Inc. Equity 3 192.800 - Ca | 1014379 BC Limited | Equity | 3 | - | | 7,500 | |
| 2459160 Ontario Inc. Warants 3 112.237 112.237 Apricon Convoing Systems Ltd. Equity 3 176.008 175.008 Apriforce Growing Systems Ltd. Warants 3 176.008 175.008 Antorneys Title Guaranty Fund Inc. Equity 3 413.000 413.000 BabelBark Inc. Equity 3 400.855 400.855 Bravio Technologies Limited Equity 3 305.25 305.25 Brazi Investments Inc. Equity 3 199.800 199.800 CannAgri Blockchain Inc. Equity 3 497.825 497.825 CannAgri Blockchain Inc. Equity 3 497.825 497.825 Cannator Investments Inc. Equity 3 497.825 497.825 Cannator Investments Inc. Equity 3 497.825 497.825 Connucr Investments Inc. Equity 3 457.825 497.825 Connucr Investments Inc. Equity 3 457.825 497.825 Connucr Investments Inc. Equity 3 456.00 - - <td>1262803 BC Ltd.</td> <td>Equity</td> <td>3</td> <td>-</td> <td></td> <td>30,000</td> <td></td> | 1262803 BC Ltd. | Equity | 3 | - | | 30,000 | |
| African Cannabis Corp. Equity 3 450.000 450.000 Agriforce Growing Systems Lld. Warrants 3 174.008 174.008 Agriforce Growing Systems Lld. Warrants 3 114.02 14.102 BabelBark Inc. Equity 3 729.618 729.618 729.618 BabelBark Inc. Equity 3 300.525 300.525 300.525 Bravio Technologies Limited Equity 3 305.479 305.479 305.479 CannAgrif Bickchain Inc. Equity 3 119.849 119.849 119.849 CannAgrif Bickchain Inc. Equity 3 190.700 - 20.275 CannAgrif Bickchain Inc. Equity 3 190.700 - 20.212 CannAgrif Bickchain Inc. Equity 3 190.700 - 20.212 CannAgrif Bickchain Inc. Equity 3 150.500 - 20.212 CannAgrif Bickchain Inc. Equity 3 150.500 - 20.212 | 2459160 Ontario Inc. | Equity | 3 | 217,763 | | 217,763 | |
| Agriforce Growing Systems Ltd. Equity 3 176.008 176.008 Antorneys Title Guaranty Fund Inc. Equity 3 413.000 413.000 BabelBark Inc. Equity 3 420.618 722.618 722.618 Brazon Technologies Limited Equity 3 400.855 400.855 Brazon Technologies Limited Equity 3 202.595 202.595 Brazon Technologies Limited Equity 3 198.800 199.800 CannAgri Blockchain Inc. Equity 3 198.802 CannAgri Blockchain Inc. Equity 3 497.825 447.825 Cannator Intervammaceuticals Corp. Equity 3 497.825 447.825 Cannator Intervammate Technology Provides Limited Equity 3 497.825 447.825 Cannator Intervammetervinets Inc. Equity 3 497.825 447.825 Cannator Intervammetervinets Inc. Equity 3 505.000 - Cannator Intervammetervinets Inc. Equity 3 <td< td=""><td>2459160 Ontario Inc.</td><td>Warrants</td><td>3</td><td>112,237</td><td></td><td>112,237</td><td></td></td<> | 2459160 Ontario Inc. | Warrants | 3 | 112,237 | | 112,237 | |
| Agridroce Growing Systems Ltd. Warrants 3 81/482 61/402 Adtomeys Title Guaranty Fund Inc. Equity 3 729.618 729.618 BabelBark Inc. Equity 3 729.618 729.618 BabelBark Inc. Equity 3 930.525 930.525 Bravio Technologies Limited Equity 3 930.5479 930.5479 Canapar Corp. Equity 3 930.5479 930.5479 Canany Grig Blockchain Inc. Equity 3 119.8490 119.849 CannArgri Blockchain Inc. Equity 3 190.700 - CarnArgri Blockchain Inc. Equity 3 930.220 - CarnArgri Blockchain Inc. Equity 3 930.220 - CarnArgri Blockchain Inc. Equity 3 930.220 - CarnArgri Blockchain Inc. Equity 3 950.500 - CarnArgri Blockchain Inc. Equity 3 951.66 - Carnandrig Blockchain Inc. Equity | African Cannabis Corp. | Equity | 3 | 450,000 | | 450,000 | |
| Agridroce Growing Systems Ltd. Warrants 3 81/422 61/402 Atomeys Title Guaranty Fund Inc. Equity 3 729.618 729.618 BabelBark Inc. Equity 3 420.000 451.000 BabelBark Inc. Equity 3 430.525 400.855 Bravio Technologies Limited Equity 3 305.479 305.479 Canapar Corp. Equity 3 930.5479 305.479 Canapar Corp. Equity 3 119.8400 119.849 CannArg IBlockchain Inc. Warrants 3 60.151 60.151 CanhArg IBlockchain Inc. Equity 3 392.820 - CarnArg IBlockchain Inc. Equity 3 932.820 - CarnArg IBlockchain Inc. Equity 3 932.820 - CarnArg IBlockchain Inc. Equity 3 95.5000 - CarnArg IBlockchain Inc. Equity 3 95.5000 - CarnArg IBlockchain Inc. Equity 3 | Agriforce Growing Systems Ltd. | Equity | 3 | 176,008 | | 176,008 | |
| Attorneys Title Guaranty Fund Inc. Equity 3 413.000 413.000 Beacon, Hill Brands Inc. Equity 3 400.855 400.855 Bravio Technologies Limited Equity 3 202.595 202.595 Brazi Investments Inc. Equity 3 202.595 202.595 Brazi Investments Inc. Equity 3 198.800 199.800 CannAgri Blockchain Inc. Equity 3 198.800 199.800 CannAgri Blockchain Inc. Equity 3 407.825 497.825 Cannoure Investments Inc. Equity 3 427.825 497.825 Cannoure Investments Inc. Equity 3 427.825 497.825 Cultivate Capital Corp. Equity 3 505.000 - Cultivate Capital Corp. Equity 3 516.600 - Cultivate Capital Corp. Equity 3 - 83.156 Danavation Technologies Equity 3 - 61.244 Danavation Technologies Equity 3 26.000 26.000 Ganavation Technologi | Agriforce Growing Systems Ltd. | Warrants | 3 | 81,492 | | 81,492 | |
| Beacon Hill Brands Inc. Equity 3 400,855 400,855 Bravio Technologies Limited Equity 3 202,595 202,595 Brazi Investment's Inc. Equity 3 202,595 202,595 Canapar Corp. Equity 3 199,800 199,840 Canapar Corp. Equity 3 190,700 - Canabar Blockchain Inc. Equity 3 392,223 - Canabar Blockchain Inc. Equity 3 392,223 - Canabar Agriculture Equity 3 - 128,128 Copeland Blosciences Corp. Equity 3 - - Danavation Tehnologies Equity 3 - - Danavation Tehnologies Equity 3 - - - Danavation Tehnologies Equity 3 - - 16,844 Elim Mining. Equity 3 - 16,844 - Elim Mining. Equity 3 260,000 </td <td></td> <td>Equity</td> <td>3</td> <td>413,000</td> <td></td> <td>413,000</td> <td></td> | | Equity | 3 | 413,000 | | 413,000 | |
| Beacon Hill Brands Inc. Equity 3 400.855 400.855 Bravio Technologies Limited Equity 3 300.225 300.325 Bravio Technologies Limited Equity 3 305.479 305.479 Canapar Corp. Equity 3 199.800 199.800 CannAgri Blockhain Inc. Equity 3 190.700 - Cannafori Blockhain Inc. Equity 3 497.825 497.825 Cannarus Towarmaeuticals Corp. Equity 3 392.820 - Cannarus Towarmeetments Inc. Equity 3 505.000 - Copeland Biosciences Corp. Equity 3 - 128.128 Coultwate Capital Corp. Equity 3 - 83.156 Danavation Tehnologies Warrants 3 - 16.444 Elim Mining. Equity 3 - 16.444 Elim Mining. Equity 3 - 16.444 Elim Mining. Equity 3 260.000 | BabelBark Inc. | Equity | 3 | 729,618 | | 729,618 | |
| Bravio Technologies Limited Equity 3 380.825 380.825 Brazil Investments Inc. Equity 3 305.479 305.479 Canapar Corp. Equity 3 199.800 199.800 CannAgr Blockchain Inc. Equity 3 119.849 119.849 CannAgr Blockchain Inc. Warrants 3 60.151 60.151 Cannaue Investments Inc. Equity 3 497.625 497.825 Canncure Investments Inc. Equity 3 505.000 - Canncure Investments Inc. Equity 3 505.000 - Cultivate Capital Corp. Equity 3 - 83.566 - Cultivate Capital Corp. Equity 3 - 83.566 - - Danavation Tehnologies Warrants 3 - 16.844 - Elmark Health Inc. Equity 3 138.509 138.509 250.002 250.002 250.002 250.002 250.002 250.002 250.002 | Beacon Hill Brands Inc. | | 3 | 400,855 | | 400,855 | |
| Brazil Investment's Inc. Equity 3 202.565 202.565 The BRN Group Inc. Equity 3 109.800 109.800 CannAgri Blockchain Inc. Equity 3 119.849 119.849 CannAgri Blockchain Inc. Equity 3 130.700 - Casters Holdings Inc. Equity 3 322.820 - Carlationer Investments Inc. Equity 3 332.820 - Correland Biosciences Corp. Equity 3 355.166 - Cultivate Capital Corp. Equity 3 - 168.444 Elim Minig. Equity 3 - 61.267 Danavation Tehnologies Equity 3 - 61.267 Embark Health Inc. Warrants 11.491 - Gadge Cannabis (Wolverine Ptnrs) Equity 3 682.500 682.500 682.500 682.500 682.500 682.500 682.500 682.500 682.500 682.500 681.267 681.67 - - 14.91 | Bravio Technologies Limited | | 3 | 360,525 | | 360,525 | |
| The BRN Group Inc. Equity 3 305,479 305,479 CannAgr Blockchain Inc. Equity 3 119,849 119,849 CannAgr Blockchain Inc. Warants 3 60,151 60,151 CannAgr Blockchain Inc. Equity 3 497,825 497,825 Cannoure Investments Inc. Equity 3 497,825 497,825 Central Coast Agriculture Equity 3 505,000 - Cultivate Capital Corp. Equity 3 505,000 - Cultivate Capital Corp. Equity 3 - 83,166 - Danavation Tehnologies Warants 3 - 16,844 - Danavation Tehnologies Warants 3 1,4,91 - - Gage Cannabis (Wolverine Ptrrs) Equity 3 138,509 138,509 Embark Health Inc. Equity 3 80,000 80,000 Gage Cannabis (Wolverine Ptrrs) Equity 3 80,491 30,491 Ganad | Brazil Investments Inc. | | 3 | | | | |
| Canapar Corp. Equity 3 199.800 199.800 CannAgr Blockchain Inc. Equity 3 110.849 119.849 CannAgr Blockchain Inc. Warrants 3 60.151 60.151 Cannboicrex Pharmaceuticals Corp. Equity 3 190.700 - Casters Holdings Inc. Equity 3 192.820 - Casters Holdings Inc. Equity 3 505.000 - Capeland Biosciences Corp. Equity 3 55.166 - Cultivate Capital Corp. Equity 3 - 18.516 Danavation Tehnologies Equity 3 - 83.156 Danavation Tehnologies Equity 3 - 15.67 Embark Health Inc. Equity 3 138.509 138.509 Gen X Biosciences Equity 3 250.000 682.200 Gen X Biosciences Equity 3 250.000 80.000 Hearth Health Inc. Equity 3 250.000 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<> | | | | | | | |
| Cann Agri Blockchain Inc. Equity 3 119.494 119.494 Cann Agri Blockchain Inc. Warrants 3 60.151 60.151 Cannbolicrex Pharmaceuticals Corp. Equity 3 497.825 497.825 Cancure Investments Inc. Equity 3 497.825 497.825 Central Coast Agriculture Equity 3 505.000 - Contrust Investments Inc. Equity 3 505.000 - Cultivate Capital Corp. Equity 3 54.66 - Cultivate Capital Corp. Warrants 3 44.834 - Danavation Tehnologies Equity 3 138.509 138.509 Embark Health Inc. Equity 3 138.509 138.509 Embark Health Inc. Equity 3 250.000 250.000 Goed Cannabis (Wolverine Ptnrs) Equity 3 260.000 250.000 Goede Inc. Equity 3 260.000 250.000 Goen X Biosciences Equity | | | | | | | |
| CannAğri Blockchain Inc. Warants 3 60,151 60,151 Cambiorex Pharmaceuticals Corp. Equity 3 497,825 497,825 Canncure Investments Inc. Equity 3 492,820 - Constard Server Investments Inc. Equity 3 392,820 - Copeland Biosciences Corp. Equity 3 56,666 - Copeland Biosciences Corp. Equity 3 56,666 - Cultivate Capital Corp. Equity 3 - 83,156 Danavation Tehnologies Equity 3 - 51,867 Danavation Tehnologies Warants 3 14,491 - Gage Cannabis (Wolverine Ptnrs) Equity 3 825,000 250,000 Goodee Inc. Equity 3 250,002 250,000 Goodee Inc. Equity 3 218,509 218,509 Heaventy RX Ltd. Equity 3 240,700 - Heaventy RX Ltd. Equity 3 240,700 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | |
| Cannobiores Pharmaceuticals Corp. Equity 3 190,700 - Casters Holdings Inc. Equity 3 497,825 497,825 Canncure Investments Inc. Equity 3 - 128,128 Contral Coast Agriculture Equity 3 505,000 - Corpeland Biosciences Corp. Equity 3 556,000 - Cultivate Capital Corp. Warrants 44,834 - - Danavation Tehnologies Warrants 3 - 16,844 Elm Mining. Equity 3 18,809 138,809 Embark Health Inc. Warrants 3 11,491 - Gage Cannabis (Wolverine Ptnrs) Equity 3 280,000 260,000 Goode Inc. Equity 3 280,000 260,000 80,000 Heavenly RX Ltd. Equity 3 208,000 80,000 80,000 Heavenly RX Ltd. Equity 3 240,700 - 108,473 130,873 130,873 | | | | | | | |
| Casters Holdings Inc. Equity 3 497,825 497,825 Canncure Investments Inc. Equity 3 392,820 - Central Coast Agriculture Equity 3 395,000 - Copeland Biosciences Corp. Equity 3 355,166 - Cultivate Capital Corp. Warrants 3 44,834 - Danavation Tehnologies Warrants 3 - 16,844 Elim Mining. Equity 3 138,509 138,509 Embark Health Inc. Equity 3 250,000 260,000 Goodee Inc. Equity 3 250,000 260,000 Goodee Inc. Equity 3 219,509 219,509 Hemp Hydrate International Equity 3 208,000 260,000 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 249,509 219,509 Legacy Eight Group Ltd. Equity 3 240,700 | | | | | | | |
| Cannoure Investments Inc. Equity 3 392,820 - Central Coast Agriculture Equity 3 505,000 - Cultivate Capital Corp. Equity 3 505,000 - Cultivate Capital Corp. Equity 3 355,166 - Danavation Tehnologies Equity 3 - 83,156 Danavation Tehnologies Warrants 3 - 16,844 Elim Mining. Equity 3 138,509 138,509 Embark Health Inc. Equity 3 138,509 682,500 Gen X Biosciences Equity 3 250,000 250,000 Gonde Inc. Equity 3 80,000 80,000 Heavenly RX Ltd. Equity 3 130,873 130,873 Impulsa Capital LCD Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 100,000 - <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | |
| Central Coast Agriculture Equity 3 - 128,128 Copeland Biosciences Corp. Equity 3 505,000 - Cultivate Capital Corp. Warrants 3 44,834 - Danavation Tehnologies Equity 3 - 16,844 Elim Mining. Equity 3 - 16,844 Elim Mining. Equity 3 - 16,844 Embark Health Inc. Equity 3 138,509 138,509 Embark Health Inc. Equity 3 280,000 260,000 Goodee Inc. Equity 3 290,000 260,000 Goodee Inc. Equity 3 219,509 219,509 Hemp Hydrate International Equity 3 30,491 30,491 Holistic Industries Inc. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 240,700 - Legacy Eight Group LLG Equity 3 50,000 26,000 | | | | | | | |
| Copeland Biosciences Corp. Equity 3 505.000 - Cultivate Capital Corp. Equity 3 355.166 - Cultivate Capital Corp. Equity 3 44.834 - Danavation Tehnologies Equity 3 - 61.644 Elim Mining. Equity 3 - 51.267 Embark Health Inc. Equity 3 138.509 138.509 Embark Health Inc. Equity 3 250.000 622.500 Gen X Biosciences Equity 3 250.000 250.000 Goode Inc. Equity 3 219.509 219.509 Hearent X Ltd. Equity 3 20.002 250.002 Hearent X Ltd. Equity 3 219.509 219.509 Hearent X Ltd. Equity 3 240.700 - Leavent X End. Equity 3 240.700 - Leavent X End. Equity 3 260.000 260.000 Miraculo I | | | | | | | |
| Cultivate Capital Corp. Equity 3 355,166 - Cultivate Capital Corp. Warrants 3 44,834 - Danavation Tehnologies Equity 3 - 68,156 Danavation Tehnologies Warrants 3 - 16,844 Elim Mining. Equity 3 138,509 138,509 Embark Health Inc. Warrants 3 11,491 - Gage Cannabis (Wolverine Phrns) Equity 3 682,500 250,002 Gen X Biosciences Equity 3 250,002 250,002 Heavenly RX Ltd. Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 260,000 250,000 Miraculo Inc. Equity 3 105,000 106,000 - Miraculo Inc. Equity 3 100, | - | | | | | | |
| Cultivate Capital Corp. Warrants 3 44,834 - Danavation Tehnologies Equity 3 - 83,156 Danavation Tehnologies Warrants 3 - 16,844 Elim Mining. Equity 3 138,509 138,509 Embark Health Inc. Equity 3 682,500 682,500 Gage Cannabis (Wolverine Ptnrs) Equity 3 250,002 280,002 Gode Inc. Equity 3 80,000 80,000 Gode Inc. Equity 3 80,000 80,000 Heavenly RX Ltd. Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 100,000 - Katexco Pharmaceuticals Corp. Equity 3 100,000 < | | | | , | | | |
| Danavation Tehnologies Equity 3 - 83,156 Danavation Tehnologies Warrants 3 - 16,844 Elim Mining, Equity 3 - 51,267 Embark Health Inc. Equity 3 138,509 138,509 Gage Cannabis (Wolverine Ptnrs) Equity 3 682,500 682,500 Goodee Inc. Equity 3 250,000 250,000 Goodee Inc. Equity 3 250,000 250,002 Heavenly RX Ltd. Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 100,000 - New Loc. Equity 3 100,000 - Net Corp. Equity 3 100,000 - | | | | , | | | |
| Danavation Tehnologies Warrants 3 - 16,844 Elim Mining. Equity 3 - 51,267 Embark Health Inc. Equity 3 138,509 138,509 Embark Health Inc. Warrants 3 11,491 - Gage Cannabis (Wolverine Ptnrs) Equity 3 682,500 682,500 Gode Inc. Equity 3 250,002 250,002 Heavenly RX Ltd. Equity 3 80,000 80,000 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 466,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 420,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 100,000 - New Inc. Equity 3 100,000 - Payfare Inc. Equity 3 100,000 - <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr<> | | | | | | | |
| Elim Mining. Equity 3 - 51,267 Embark Health Inc. Equity 3 138,509 138,509 Embark Health Inc. Warrants 3 11,491 - Gage Cannabis (Wolverine Ptnrs) Equity 3 682,500 682,500 Goodee Inc. Equity 3 250,000 250,000 Goodee Inc. Equity 3 80,000 80,000 Hearvenly RX Ltd. Equity 3 219,509 219,509 Hemp Hydrate International Equity 3 0,491 30,491 Holistic Industries Inc. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 466,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 105,000 105,000 Miraculo Inc. Equity 3 100,000 - Newt Inc. Equity 3 100,000 - Newt Inc. Equity 3 100,000 100,000 <tr< td=""><td>0</td><td></td><td></td><td></td><td></td><td>,</td><td></td></tr<> | 0 | | | | | , | |
| Embark Health Inc. Equity 3 138,509 138,509 Embark Health Inc. Warrants 3 11,491 - Gage Cannabis (Wolverine Ptnrs) Equity 3 682,500 682,500 Gen X Biosciences Equity 3 250,000 250,000 Goodee Inc. Equity 3 250,000 260,000 Heavenly RX Ltd. Equity 3 210,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 100,000 100,000 Molecular Science Corp. Equity 3 100,000 - New Inc. Equity 3 100,000 50,000 Payfare Inc. Equity 3 100,000 - New Inc. Equity 3 100,000 100,000 | | | | - | | | |
| Embark Health Inc. Warrants 3 11.491 - Gage Cannabis (Wolverine Ptnrs) Equity 3 682,500 682,500 Gode X Biosciences Equity 3 250,000 250,000 Goodee Inc. Equity 3 250,002 250,002 Heavenly RX Ltd. Equity 3 80,000 80,000 Hemp Hydrate International Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 66,510 66,510 Katexo Pharmaceuticals Corp. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 105,000 105,000 Miraculo Inc. Equity 3 100,000 - - Newt Inc. Equity 3 100,000 - - Newt Inc. Equity 3 100,000 - - Prominex Resources Corp. Equity | | | | - | | | |
| Gage Cannabis (Wolverine Ptnrs) Equity 3 682,500 682,500 Gen X Biosciences Equity 3 250,000 250,000 Goodee Inc. Equity 3 250,000 250,002 Heavenly RX Ltd. Equity 3 80,000 80,000 Hemp Hydrate International Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 420,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 Molecule Inc. Equity 3 100,000 - Newt Inc. Equity 3 100,000 - Promedia Investments Incorporated Equity 3 263,120 263,120 Promedia Investments Incorporated Equity 3 | | | | | | | |
| Gen X Biosciences Equity 3 250,000 250,000 Goodee Inc. Equity 3 250,002 250,002 Heavenly RX Ltd. Equity 3 80,000 80,000 Hemp Hydrate International Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 420,700 - Legacy Eight Group Ltd. Equity 3 105,000 105,000 Miraculo Inc. Equity 3 100,000 - New Inc. Equity 3 100,000 - Newt Inc. Equity 3 100,000 - Pluribus Technologies Inc. Equity 3 100,000 - Promedia Investments Incorporated Equity 3 140,000 140,000 S1 capital Corp. Equity 3 140,000 50,0 | | | | | | | |
| Goodee Inc. Equity 3 250,002 250,002 Heavenly RX Ltd. Equity 3 80,000 80,000 Hemp Hydrate International Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 Molecular Science Corp. Equity 3 100,000 - Newt Inc. Equity 3 100,000 - Payfare Inc. Equity 3 100,000 - Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 260,000 140,000 Prominex Resources Corp. Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 | | | | | | | |
| Heavenly RX Ltd. Equity 3 80,000 80,000 Hemp Hydrate International Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 105,000 Molecule Inc. Equity 3 100,000 - - Newt Inc. Equity 3 100,000 - - Newt Inc. Equity 3 100,000 100,000 - Promedia Investments Incorporated Equity 3 263,120 263,120 263,120 Prominex Resources Corp. Equity 3 140,000 140,000 140,000 StreenPro Security Ltd. Equity 3 50,000 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<> | | | | | | | |
| Hemp Hydrate International Equity 3 219,509 219,509 Hemp Hydrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 105,000 105,000 Miraculo Inc. Equity 3 250,000 250,000 Molecular Science Corp. Equity 3 100,000 - Newt Inc. Equity 3 100,000 - Payfare Inc. Equity 3 100,000 100,000 Pluribus Technologies Inc. Equity 3 263,120 263,120 Promedia Investments Incorporated Equity 3 140,000 140,000 ScreenPro Security Ltd. Equity 3 - 20,000 ScreenPro Security Ltd. Equity 3 | | | | | | | |
| Hemp Hýdrate International Warrants 3 30,491 30,491 Holistic Industries Inc. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 250,000 250,000 Molecular Science Corp. Equity 3 100,000 - Newt Inc. Equity 3 50,000 50,000 Pafare Inc. Equity 3 100,000 - Newt Inc. Equity 3 263,120 263,120 Pafare Inc. Equity 3 263,120 263,120 Promeia Investments Incorporated Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 50,000 50,000 S0,000 ScreenPro Security Ltd. Equity 3 - <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | |
| Holistic Industries Inc. Equity 3 130,873 130,873 Impulsa Capital LLC Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 Molecular Science Corp. Equity 3 250,000 - Newt Inc. Equity 3 50,000 - Newt Inc. Equity 3 100,000 - Payfare Inc. Equity 3 263,120 263,120 Promedia Investments Incorporated Equity 3 140,000 140,000 Prominex Resources Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 71,857 71,857 Somersby Park 2010 Ltd Partnership Equity 3 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<> | | | | | | | |
| Impulsa Capital LLC Equity 3 66,510 66,510 Katexco Pharmaceuticals Corp. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 Molecular Science Corp. Equity 3 250,000 250,000 Molecular Science Corp. Equity 3 50,000 - Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 100,000 - Pluribus Technologies Inc. Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 140,000 140,000 Sol Capital Corp. Equity 3 - 20,000 ScreenPro Security Ltd. Equity 3 - 20,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 | | | | | | | |
| Katexco Pharmaceuticals Corp. Equity 3 240,700 - Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 Molecular Science Corp. Equity 3 250,000 250,000 Molecule Inc. Equity 3 100,000 - Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 100,000 - Newt Inc. Equity 3 263,120 263,120 Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 - 20,000 ScreenPro Security Ltd. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 200,000 200,000< | | | | | | | |
| Legacy Eight Group Ltd. Equity 3 427,180 427,180 Miraculo Inc. Equity 3 105,000 105,000 Molecular Science Corp. Equity 3 250,000 250,000 Molecule Inc. Equity 3 100,000 - Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 100,000 100,000 Pluribus Technologies Inc. Equity 3 263,120 263,120 Promedia Investments Incorporated Equity 3 140,000 140,000 ScreenPro Security Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 ScreenPro Security Ltd. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<> | | | | | | | |
| Miraculo Inc. Equity 3 105,000 105,000 Molecular Science Corp. Equity 3 250,000 250,000 Molecule Inc. Equity 3 100,000 - Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 50,000 50,000 Pluribus Technologies Inc. Equity 3 - 149,971 Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 - 20,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 200,000 200,000 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | |
| Molecular Science Corp. Equity 3 250,000 250,000 Molecule Inc. Equity 3 100,000 - Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 50,000 100,000 Pluribus Technologies Inc. Equity 3 - 149,971 Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 140,000 140,000 Scieprocity Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 772,079 772,079 Southern Sky Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - | | | | | | | |
| Molecule Inc. Equity 3 100,000 - Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 100,000 100,000 Pluribus Technologies Inc. Equity 3 - 149,971 Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 18,650 18,650 Reciprocity Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 140,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 99,999 99,999 Southern Sky Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - | | | | | | | |
| Newt Inc. Equity 3 50,000 50,000 Payfare Inc. Equity 3 100,000 100,000 Pluribus Technologies Inc. Equity 3 - 149,971 Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 18,650 18,650 Reciprocity Corp. Equity 3 50,000 140,000 S1 Capital Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 99,999 99,999 Southern Sky Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | • | Equity | | | | 250,000 | |
| Payfare Inc. Equity 3 100,000 100,000 Pluribus Technologies Inc. Equity 3 - 149,971 Promedia Investments Incorporated Equity 3 263,120 263,120 Prominex Resources Corp. Equity 3 18,650 18,650 Reciprocity Corp. Equity 3 50,000 140,000 S1 Capital Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | | Equity | | 100,000 | | - | |
| Pluribus Technologies Inc.Equity3-149,971Promedia Investments IncorporatedEquity3263,120263,120Prominex Resources Corp.Equity318,65018,650Reciprocity Corp.Equity3140,000140,000S1 Capital Corp.Equity350,00050,000ScreenPro Security Ltd.Equity3-20,000Sentia Wellness, Inc.Equity3-71,857Somersby Park 2010 Ltd PartnershipEquity3772,079772,079Southern SkyEquity399,99999,999Taste Brands Corp.Equity3192,000200,000Trait Biosciences IncorporatedEquity3-31,938 | | Equity | | 50,000 | | 50,000 | |
| Promedia Investments IncorporatedEquity3263,120263,120Prominex Resources Corp.Equity318,65018,650Reciprocity Corp.Equity3140,000140,000S1 Capital Corp.Equity350,00050,000ScreenPro Security Ltd.Equity3-20,000Sentia Wellness, Inc.Equity3-71,857Somersby Park 2010 Ltd PartnershipEquity3772,079772,079Southern SkyEquity399,99999,999Taste Brands Corp.Equity3200,000200,000Trait Biosciences IncorporatedEquity3192,000192,000Tripsitter Clinic CorpEquity3-31,938 | | Equity | | 100,000 | | 100,000 | |
| Prominex Resources Corp. Equity 3 18,650 18,650 Reciprocity Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | | | | | | | |
| Prominex Resources Corp. Equity 3 18,650 18,650 Reciprocity Corp. Equity 3 140,000 140,000 S1 Capital Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | · · · · · · · · · · · · · · · · · · · | Equity | | 263,120 | | 263,120 | |
| S1 Capital Corp. Equity 3 50,000 50,000 ScreenPro Security Ltd. Equity 3 - 20,000 Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | | | 3 | 18,650 | | 18,650 | |
| ScreenPro Security Ltd.Equity3-20,000Sentia Wellness, Inc.Equity3-71,857Somersby Park 2010 Ltd PartnershipEquity3772,079772,079Southern SkyEquity399,99999,999Taste Brands Corp.Equity3200,000200,000Trait Biosciences IncorporatedEquity3192,000192,000Tripsitter Clinic CorpEquity3-31,938 | Reciprocity Corp. | Equity | 3 | 140,000 | | 140,000 | |
| Sentia Wellness, Inc. Equity 3 - 71,857 Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | | Equity | 3 | 50,000 | | 50,000 | |
| Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | | Equity | 3 | - | | 20,000 | |
| Somersby Park 2010 Ltd Partnership Equity 3 772,079 772,079 Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | Sentia Wellness, Inc. | Equity | 3 | - | | 71,857 | |
| Southern Sky Equity 3 99,999 99,999 Taste Brands Corp. Equity 3 200,000 200,000 Trait Biosciences Incorporated Equity 3 192,000 192,000 Tripsitter Clinic Corp Equity 3 - 31,938 | Somersby Park 2010 Ltd Partnership | | 3 | 772,079 | | 772,079 | |
| Taste Brands Corp.Equity3200,000200,000Trait Biosciences IncorporatedEquity3192,000192,000Tripsitter Clinic CorpEquity3-31,938 | | | | | | | |
| Trait Biosciences IncorporatedEquity3192,000192,000Tripsitter Clinic CorpEquity3-31,938 | | | | | | | |
| Tripsitter Clinic Corp Equity 3 - 31,938 | | | | | | | |
| | | | | | | | |
| Private company investments - FVIPL \$ 10717250 \$ 10.095197.8 9.467200 \$ 7.35 | Private company investments - FVTPL | | ~ | \$ 10,717,250 \$ | 10,095,197 \$ | 9,467,200 \$ | 7,358,287 |



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

6. INVESTMENTS - FVTPL (continued)

| | | Financial instr. | Dec. 31 | · | ec. 31, 2020 |
|-----------------------------------|------------|------------------|------------|-----------------|--------------|
| Investment | Instrument | hierarchy | Cost | Fair value Cost | Fair value |
| 180 Life Sciences Corp. | Equity | 1 | - | 314 | ,730 |
| 3 Sixty Risk Solutions Ltd. | Equity | 1 | \$ 110,857 | \$- | |
| 79North Ltd. | Equity | 1 | - | | ,000 |
| Abraplata Resources Corp. | Equity | 1 | - | | ,706 |
| Abraplata Resources Corp. | Warrants | 2 | - | 3 | ,301 |
| Advantagewon Oil Corp. | Equity | 1 | 245,456 | 152 | ,289 |
| Aris Gold Corp. (Caldas Gold) | Equity | 1 | - | 21 | ,030 |
| Aris Gold Corp. (Caldas Gold) | Warrants | 2 | - | 12 | ,720 |
| Arizona Metals Corp. | Equity | 1 | - | 54 | ,405 |
| Artemis Gold Inc. | Equity | 1 | 16,318 | - | |
| Artemis Gold Inc. | Warrants | 2 | 10,682 | - | |
| BevCanna Enterprises Inc. | Equity | 1 | 50,000 | - | |
| Bluma Wellness Inc. | Equity | 1 | - | 423 | ,886 |
| Bragg Gaming Group | Equity | 1 | 817,062 | 67 | ,872 |
| Bragg Gaming Group | Warrants | 2 | 106,263 | 28 | ,434 |
| Canntrust Holdings Inc. | Warrants | 2 | 20,458 | - | |
| Cansortium Inc. | Equity | 1 | 2,834,575 | 2,834 | ,575 |
| Cansortium Inc. | Warrants | 2 | 528,545 | 528 | ,545 |
| Captor Capital Corp. | Warrants | 2 | 36,268 | - | |
| CGX Energy Inc. | Equity | 1 | 52,660 | - | |
| Cryptologic Corp. | Equity | 1 | - | 236 | ,610 |
| Cryptologic Corp. | Warrants | 2 | 110,393 | - | |
| Curaleaf Holdings Inc. | Equity | 1 | - | 69 | ,511 |
| Emerge Commerce | Equity | 1 | - | | ,000 |
| Docebo Inc. | Equity | 1 | 240 | - | |
| Eco Atlantic Oil & Gas Inc. | Equity | 1 | 67,238 | - | |
| Engine Media Holdings Inc. | Equity | 1 | 99,993 | 61 | ,190 |
| Engine Media Holdings Inc. | Warrants | 2 | 18,030 | | ,030 |
| Global Health Clinics Ltd. | Equity | 1 | - | | ,661 |
| Global Health Clinics Ltd. | Warrants | 2 | - | | ,339 |
| Global Care Capital Inc. | Warrants | 2 | - | | ,793 |
| Green Growth Brands Ltd. | Equity | 1 | 1,938,677 | - | |
| Green Growth Brands Ltd. | Warrants | 2 | 176,997 | - | |
| High Tide Inc. | Equity | 1 | 283,022 | 236 | ,001 |
| HTC Purenergy Inc. | Equity | 1 | 41,866 | - | |
| HTC Purenergy Inc. | Warrants | 2 | 38,432 | 38 | ,432 |
| Isracann Biosciences Inc. | Equity | 1 | 34,000 | - | |
| Kew Media Inc. | Equity | 1 | 81,545 | - | |
| Kew Media Inc. | Warrants | 2 | 315,000 | - | |
| Kwesst Micro Systems | Equity | 1 | - | 409 | ,911 |
| Lendified Holdings Inc. | Equity | 1 | - | 20 | ,000 |
| Liberty Health Sciences Inc. | Warrants | 2 | 64,539 | - | |
| Maritime Resources Corp. | Equity | 1 | - | 39 | ,998 |
| Nighthawk Gold Corp. | Equity | 1 | - | 66 | ,877 |
| Nighthawk Gold Corp. | Warrants | 2 | - | g | ,623 |
| Nova Mentis Life Science Corp. | Equity | 1 | - | 26 | ,500 |
| Organto Foods Inc. | Equity | 1 | 10,109 | - | |
| Pacific Rim Cobalt Corp. | Warrants | 2 | 8,198 | - | |
| Pampa Metals Corp. | Equity | 1 | - | 40 | ,000 |
| Pivotree Inc. | Equity | 1 | - | 25 | ,500 |
| Plant & Co Brands Ltd. | Equity | 1 | - | 40 | ,000 |
| Popreach Incorporated | Equity | 1 | - | 187 | ,500 |
| Popreach Incorporated | Warrants | 2 | - | | ,229 |
| Prismo Metals Inc. | Equity | 1 | - | | ,785 |
| Psyched Wellness (Duncan Park) | Equity | 1 | - | | ,962 |
| Reconnaissance Energy Africa Ltd. | Warrants | 2 | - | | ,155 |
| Red White & Bloom Brands Inc. | Equity | 1 | 528,034 | - | |
| Red White & Bloom Brands Inc. | Warrants | 2 | 15,361 | - | |
| Rise Life Sciences Corp. | Warrants | 2 | 98,204 | - | |
| Relig Health Technologies | Equity | 1 | | 82 | ,881 |
| | | | | | |



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

6. INVESTMENTS - FVTPL (continued)

| | | Financial instr. | Dec. 31, 2 | 019 | Dec. 31, 2 | 2020 |
|------------------------------------|------------|------------------|---------------------|---------------|----------------------|------------|
| Investment | Instrument | hierarchy | Cost | Fair value | Cost | Fair value |
| Salona Global Medical | Equity | 1 | - | 46,357 | | |
| Salona Global Medical | Warrants | 2 | - | | 3,643 | |
| Saturn Oil & Gas Inc. | Warrants | 2 | 110,977 | | - | |
| Simply Inc. (Cool Holdings Inc.) | Equity | 1 | - | | 627,837 | |
| Simply Inc. (Cool Holdings Inc.) | Warrants | 2 | 475,488 | | 518,080 | |
| Slang Worldwide Inc. | Equity | 1 | - | | 208,001 | |
| SOL Global Investments Corp. | Equity | 1 | 602,764 | - | | |
| Spectra7 Microsystems Inc. | Equity | 1 | 919,788 | - | | |
| Spectra7 Microsystems Inc. | Warrants | 2 | 60,885 | 60,885 | | |
| Sweet Natural Trading Co. Ltd | Equity | 1 | 225,339 | - | | |
| Sweet Natural Trading Co. Ltd | Warrants | 2 | 19,917 | - | | |
| Talisker Resources Ltd. | Equity | 1 | - | 34,588 | | |
| Talisker Resources Ltd. | Warrants | 2 | - | | 5,412 | |
| Vision Marine Technologies | Equity | 1 | - | | 158,505 | |
| Turmalina Metals Corp. | Warrants | 2 | - | | 12,246 | |
| Wayland Group Corp. | Equity | 1 | 741,761 | - | | |
| Wayland Group Corp. | Warrants | 2 | 296,479 | - | | |
| Zoomd Technologies Ltd. | Equity | 1 | 473,000 | | - | |
| Public company investments - FVTPL | | | \$ 12,685,420 \$ | 4,311,100 \$ | 8,221,776 \$ | 8,635,111 |
| | | | \$ 23,402,670 \$ | 14,406,297 \$ | 17,688,976 \$ | 15,993,398 |

7. SUBSIDIARIES AND ASSOCIATES

The Company's subsidiaries are as follows:

| Subsidiary/Associate | 2020 Ownership | 2019 Ownership | Place of business |
|--|-------------------|-------------------|-------------------|
| Fountain Advisor's Corp. | 100% | 0% | Canada |
| Somersby Park 2010 Limited Partnership | 73% | 73% | United States |
| Auto repair finance company | 50% | 50% | Canada |
| Foothills Development Inc. | 0% | 0% | United States |
| Newborn Realty Corporation | 0% | 0% | United States |

Fountain Advisor's Corp. was incorporated in January 2020.

The Company is the parent company of the general partner of GC Global Capital Lending Partners Limited Partnership and Somersby Park 2010 General Partner Inc. (Somersby). The General Partner has unlimited liability for the liabilities and obligations of the partnerships in excess of the contributions of the limited partners. As at December 31, 2020, there were no outstanding liabilities or obligations for which the Company was contingently liable.

Somersby Park 2010 Limited Partnership (Somersby) owned vacant real estate in the United States which was sold during the year ended December 31, 2020.

Foothills Development Inc. and Newborn Realty Corporation were dissolved on December 31, 2019.

The auto repair finance company filed for receivership in December 2019.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

8. FAIR VALUE MEASUREMENTS

The following table presents the Company's financial assets as categorized on the statement of financial position measured at fair value and classified into levels of the fair value hierarchy:

| As at December 31, 2020 | Level 1 | Level | 2 | Level 3 |
|--|--------------------------------|----------|------------------------|------------------------------|
| Cash and short term investments Loans and convertible debt - FVTPL Investments - FVTPL | \$ 1,062,934 - 7,130,482 | 313 | - \$ 3,507 4,629 | - 985,688 7,358,287 |
| | \$ 8,193,416 | \$ 1,818 | 3,136 \$ | 8,343,975 |
| As at December 31, 2019 | Level 1 | Level | 2 | Level 3 |
| Cash and short term investments Loans and convertible debt - FVTPL Investments - FVTPL | \$ 375,537 - 3,744,717 | 1,279 | - \$ 9,254 6,159 | - 1,706,308 10,095,421 |
| | \$ 4,120,254 | | 5,413 \$ | 11,801,729 |

Fair value estimation

The Company's management review and approve the valuation results of all investments in the portfolio based on all observable and non-observable inputs. The Company also will engage an independent valuation firm to perform an independent valuation in situations where it requires additional expertise. The valuation results are reviewed with the audit committee as part of its quarterly approval of the Company's consolidated financial statements.

The fair value of the Company's investments is determined as follows:

Listed securities

The fair value of securities traded in active markets are based on quoted market prices at the close of trading on the reporting date. The Company uses the last traded market price where the last traded price falls within the bidask spread. In circumstances where the last traded price is not within the bid-ask spread, the Company determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. The fair value of securities that are subject to trading restrictions are recorded at a value which takes into account the length and nature of the restrictions, if needed.

Unlisted securities

For investments that are not publicly traded, subsequent to initial recognition, the fair value of these investments is determined by the Company using the most appropriate valuation methodology in light of the nature, facts and circumstances of the investment and its materiality in the context of the total investment portfolio.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

8. FAIR VALUE MEASUREMENTS (continued)

For unlisted equity instruments:

- Investments are valued at cost for a limited period after the date of acquisition, if the purchase price remains representative of the fair value at the reporting date; otherwise, investments are valued using one of the other methodologies detailed below.
- Investments in which there has been a recent or in-progress funding round involving significant financing from external investors are valued at the price of the recent funding, whereby the various shareholder categories rights are taken into account in the valuation. The price is adjusted, where appropriate.
- Investments in which there has been a recent private secondary market trade of meaningful volume and the transaction is undertaken by a sophisticated, arm's-length investor are valued at the price of the recent trade.
- Investments in established companies for which there has not been any recent independent funding or secondary private market transaction are valued by using revenue or earnings multiples. When valued on a multiple basis, the maintainable revenue or earnings of a portfolio company are multiplied by an appropriate multiple. The multiple is derived from the market capitalization of a peer group. Companies are selected for the peer group that are comparable with the portfolio company to be valued as to their business model and size. If the portfolio company to be valued differs in certain aspects compared with features of companies in the peer group, discounts or premiums are applied to the relevant multiple or resulting valuation.
- Investments in early-stage companies not generating sustainable revenue or earnings and for which there has not been any recent independent funding are valued using alternative methodologies. The Company considers investee company performance relative to plan, going concern risk, continued funding availability, comparable peer group valuations, exit market conditions and general sector conditions and calibrates its valuation of each investment as appropriate.
- For public company warrants, options and conversion features on debt (i.e., the underlying security of which is traded on a recognized stock exchange), valuation models such as Black-Scholes are used when there are sufficient and reliable observable market inputs. These market inputs include risk-free interest rate, exercise price, market price at date of valuation, expected dividend yield, expected life of the instrument and expected volatility of the underlying security based on historical volatility. For private company warrants, the underlying security is not traded on a recognized stock exchange, therefore fair value is determined consistent with other investments that do not have an active market, as described above.
- Loans, debentures and promissory notes issued by investees are generally valued at the price at which the instrument was issued. The Company regularly considers whether any indications of deterioration in the value of the underlying business exist, which suggest that the debt instrument will not be fully recovered. The fair value of convertible debentures receivable is measured using valuation techniques including discounted cash flow models and modified Black Scholes option pricing models. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgment and assumptions provided by Management is required in establishing fair values. Judgements include consideration of inputs such as credit risk, discount rates, volatility, probability of certain triggering events and IPO events, and share prices of private company borrowers. Changes in assumptions relating to these factors could affect the reported fair value of the financial instruments.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

8. FAIR VALUE MEASUREMENTS (continued)

The Company may apply a further illiquidity discount to the fair value of an investment if conditions exist that could make it challenging to monetize the investment in the near term at a price indicated by the valuation models. The amount of illiquidity discount applied requires considerable judgment and is based on the facts and circumstances of each investment.

The process of valuing investments for which no active market exists is inevitably based on inherent uncertainties, and the resulting values may differ significantly from values that would have been used had a ready market existed for the investments. These differences could be material to the fair value of investments in the portfolio.

During the year ended December 31, 2020, the reconciliation of investments measured at fair value using unobservable inputs (Level 3) is presented as follows:

| Balance - December 31, 2020 | \$ 8,343,975 |
|-------------------------------------|------------------|
| Change in unrealized gains (losses) | 1,559,022 |
| Realized losses | (3,754,467 |
| Dispositions | (1,624,842 |
| Purchases | 462,533 |
| Transfers (to) from Level 1 | (100,000 |
| alance - December 31, 2019 | \$ 11,801,729 |
| Change in unrealized gains (losses) | (5,415,811 |
| Dispositions | (2,246,367 |
| Purchases | 4,984,901 |
| Transfers (to) from Level 2 | (566,159 |
| Transfers (to) from Level 1 | (3,293,119 |
| alance - December 31, 2018 | \$ 18,338,284 |

The table below presents the valuation techniques and the nature of significant inputs used to determine the fair values of the Level 3 investments as at December 31, 2020:

| | | | Fair Value Change |
|--------------------|-----------------------------------|--|-------------------|
| Investment | Method | Inputs | + / - 10% |
| Equity Instruments | Transaction price | Recent purchase price | 1,440,416 |
| Convertible Debt | Black Scholes model on conversion | Market prices, volatility, discount rate | 129,920 |
| Warrants | Black Scholes model | Market prices, volatility, discount rate | 158,924 |



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

9. SHARE CAPITAL

(a) Authorized Capital

Unlimited number of:

Multiple voting shares ("MVS")

Subordinate voting shares ("SVS")

Preferred shares

The rights of MVS and SVS shares are identical other than voting rights. MVS shares are entitled to four votes per share whereas SVS shares are entitled to one vote per share.

(b) Issued

| Number of | 0 |
|---------------------|--|
| snares | Consideration |
| 88,360 | \$ 161,122 |
| (600) | (1,094) |
| 87,760 | \$ 160,028 |
| Number of shares | Consideration |
| 58,906,102 | \$ 28,992,235 |
| 600 | 1,094 |
| 58,906,702 | 28,993,329 |
| 2,870,000 | 645,750 |
| 61,776,702 | \$ 29,639,079 |
| 61,864,462 | \$ 29,799,107 |
| | shares 88,360 (600) 87,760 Number of shares 58,906,102 600 58,906,702 2,870,000 61,776,702 |

(c) Contributed Surplus

Share-based Payment Reserve

| Balance - December 31, 2020 | \$ 6,524,036 |
|-----------------------------|-----------------|
| Stock-based compensation | 154,443 |
| Balance - December 31, 2019 | \$ 6,369,593 |
| Stock-based compensation | 316,366 |
| Balance - December 31, 2018 | \$ 6,053,227 |

Stock Options

The Company has a stock option plan (the "**Plan**") which was approved by the Board of Directors of the Company. The total number of shares reserved for issuance under the Plan is equal to 10% of the outstanding Subordinate Voting Shares.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

9. SHARE CAPITAL (continued)

(c) Contributed Surplus (continued)

The Plan is for the benefit of the employees, officers and directors of the Company. The Plan is administered by the Compensation Committee of the Board of Directors of the Company. The Compensation Committee may from time to time designate individuals to whom options to purchase shares of the capital stock of the Company may be granted, the number of shares to be optioned to each and the vesting terms of such options. The option price per share which is the subject of any option shall be fixed by the Board of Directors when such option is granted. The option price can be discounted according to the rules of the Exchange at the time the option is granted. The options may not be assigned, transferred or pledged. Subject to any grace period allowed under the policies of the Exchange, and notwithstanding any specific agreements with the Company, the options will expire upon the termination of the employment or office with the Company or any of its subsidiaries or death of an individual. The total number of shares to be optioned to any one individual cannot exceed five percent of the total of the issued and outstanding shares. It has been the Company's policy for options to vest upon issuance, however it remains open to change at the Board's discretion.

| | Number of options | Weighted average exercise price |
|--------------------------------------|-------------------|---------------------------------------|
| Balance - December 31, 2018 and 2019 | 3,805,000 | \$ 0.43 |
| Granted | 1,275,000 | 0.15 |
| Balance - December 31, 2020 | 5,080,000 | \$ 0.36 |

During the years ended December 31, 2020 and 2019, the following stock options were issued and valued using the Black-Scholes option pricing model parameters listed below (in each case with no dividends and a nil forfeiture rate):

| | | | Black | | | | |
|---------------|----------------------|-------------------|------------------------|------------------|------------------------|----------------------|------------|
| Expiry date | Number of options | Exercise price | Grant date share price | Interest rate | Expiry date (years) | Volatility factor | Fair value |
| July 16, 2025 | 1,275,000 | \$0.145 | \$0.14 | 1.30% | 5.0 | 107% | \$0.11 |

The fair value of the options was estimated at \$137,445 using the Black-Scholes pricing model with the following assumptions as described above. The vested fair value recorded during the years December 31, 2020 was \$80,176.

Stock Options (continued)

A summary of the Company's outstanding stock options at December 31, 2020 is presented below:

| Grant date | Options outstanding | Options exercisable | Exercise price | Weighted average remaining life (years) |
|-------------------|---------------------|---------------------|----------------|---|
| June 5, 2014 | 230,000 | 230,000 | \$0.40 | 3.4 |
| January 23, 2017 | 350,000 | 350,000 | \$0.30 | 1.1 |
| November 8, 2017 | 1,100,000 | 1,100,000 | \$0.3625 | 1.8 |
| June 4, 2018 | 1,250,000 | 1,250,000 | \$0.455 | 2.4 |
| August 31, 2018 | 300,000 | 200,000 | \$0.455 | 2.7 |
| November 29, 2018 | 575,000 | 383,334 | \$0.505 | 2.9 |
| July 16, 2020 | 1,275,000 | 425,000 | \$0.145 | 4.5 |
| | 5,080,000 | 3,938,334 | \$0.35 | 2.9 |

Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

9. SHARE CAPITAL (continued)

(c) Contributed Surplus (continued)

Option pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Volatility is based on the historical volatility of the Company. Changes in the underlying assumptions can materially affect the fair value estimates. The options issued to non-employees were valued using the fair value of the equity instrument granted in the absence of a reliable estimate of the fair value of the goods or services received.

FOUNTAIN ASSET

10. SUPPLEMENTAL CASH FLOW INFORMATION

| For the years ended December 31, | 2020 | 2019 |
|----------------------------------|------------------|---------|
| Interest income received | \$ 175,419 \$ | 326,150 |
| Interest paid | \$ - \$ | 7,803 |

11. COMPENSATION OF KEY MANAGEMENT

The remuneration of directors and other key management personnel of the Company consisted of the following:

| For the years ended December 31, | 2020 | | 2019 |
|----------------------------------|-----------|-----|---------|
| Cash compensation | \$ 267,00 | | 288,750 |
| Fair value of stock options | 154,44 | 3 | 316,366 |
| | \$ 421,44 | 3\$ | 605,116 |

Key consultants and management of the Company are entitled to an annual incentive bonus based on the performance of the Company's investment portfolio. The bonus pool will be based on certain performance metrics based on the Company's net realized capital gains, plus interest and dividends over certain hurdle rates, calculated on an annual basis. As at December 31, 2020, \$nil was accrued for the 2020 annual incentive plan (December 31, 2019 - \$2,085,394). During the year, \$374,888 was paid on the prior year accrual. In addition, \$1,435,000 was settled in shares (see note 9) resulting in a gain of \$789,250. Of the amount settled in shares, \$30,000 was issued to Andrew Parks, the President and Chief Executive Officer of the Company. In addition, a further \$275,506 was forgiven by Mr. Parks.

12. RELATED PARTY TRANSACTIONS

The aggregate value of transactions and outstanding balances relating to directors and executive management and entities over which they have control or significant influence were as follows:

| | | | | | mounts Rece December 31 2020 | | e/Investment ecember 31, 2019 |
|------------------------|-------------------|----------------------|--------------------------|---------|------------------------------------|--------|-------------------------------------|
| Somersby Park 2010 Lin | nited Partnership | | | \$ | 316,95 | 9\$ | 600,825 |
| | | | tion value ears ended | | Balance outs | tandir | ıg as at |
| Transaction | Note | December 31, 2020 | December 2019 | , | ember 31, 2020 | De | cember 31, 2019 |
| Consulting | (1) | \$ 60,000 | \$ 60 | ,000 \$ | - | \$ | - |

(1) During the year ended December 31, 2020, the Company paid financial consulting fees of \$60,000 (2019 - \$60,000) to 2245448 Ontario Inc., a company controlled by Michael Leskovec, the Chief Financial Officer of the Company. At December 31, 2020, the balance owed was \$nil (December 31, 2019 - \$nil).

These transactions have been recorded at the exchange amounts established and agreed to by the related parties.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

12. RELATED PARTY TRANSACTIONS (continued)

The Company often receives the right to nominate a member to the Board of Directors of companies to which it provides an investment. The nominees may be of the Company, and accordingly, the investee company may become related to the Company. The table below identifies the related party, the name of the related officer or director of the Company and the position they held with the investee company.

| Investment | Ownership | Officer/Director Name | Position Held |
|--|-----------|-----------------------|---------------|
| BabelBark Inc. | <10% | Paul Kelly | Director |
| CannAgri Blockchain Inc. | <10% | Michael Galloro | Director |
| Cansortium Inc. | <10% | Roger Daher | Director |
| Global Health Clinic | <10% | Andrew Parks | Director |
| Nighthawk Gold Corp. | <10% | Morris Prychidny | Director |
| Nighthawk Gold Corp. | <10% | Michael Leskovec | Officer |
| Prominex Resources Corp. | <10% | Andrew Parks | Director |
| Simply, Inc. | <10% | Michael Galloro | Director |
| Somersby Park 2010 Limited Partnership | <10% | Andrew Parks | Director |
| Talisker Resources Ltd. | <10% | Morris Prychidny | Officer |
| The BRN Group Inc. | <10% | Andrew Parks | Director |
| Tripsitter Clinic Corp | <10% | Andrew Parks | Director |

13. CAPITAL MANAGEMENT

The primary goals of the Company's risk management programs are to ensure that the outcomes of activities involving elements of risk are consistent with the Company's objectives and risk tolerance. The Company's investment strategy requires a level of risk in exchange for an above average return on investment. The Company plans to maintain an appropriate risk and reward balance while protecting the Company's financial operations from events that have the potential to materially impair its financial strength. Balancing risk and reward is achieved through aligning risk tolerance with the Company's business strategy, diversifying risk, pricing appropriately for risk, mitigating risk through preventative controls and transferring risk to third parties.

The Company includes the following in its capital:

| As at December 31, | 2020 | 2019 |
|-----------------------------------|------------------|--------------|
| Shareholders' equity comprised of | | |
| Share capital | \$ 29,799,107 \$ | 29,153,357 |
| Contributed surplus | 6,524,036 | 6,369,593 |
| Deficit | (17,065,861) | (19,642,473) |
| | \$ 19,257,282 \$ | 15,880,477 |

There were no changes to the Company's capital management objectives during the period. The Company's objectives when managing capital are:

- (a) to ensure that the Company maintains the level of capital necessary to meet the requirements of its brokers and bank;
- (b) to allow the Company to respond to changes in economic and/or marketplace conditions by maintaining the Company's ability to purchase new investments;
- (c) to give shareholders sustained growth in shareholder value by increasing shareholders' equity. It is the intention of the Company in the long term to pay out a portion of its future annual earnings to shareholders in the form of dividends; and
- (d) to maintain a flexible capital structure which optimizes the cost of capital at acceptable levels of risk.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

13. CAPITAL MANAGEMENT (continued)

There were no changes to the way the Company manages its capital structure during the period. The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk of its underlying assets. The Company has the ability to maintain or adjust its capital level to enable it to meet its objectives by:

- (a) realizing proceeds from the disposition of its investments;
- (b) utilizing leverage in the form of margin (due to brokers) and long-term debt from financial lenders; and
- (c) raising capital through equity financings.

14. INCOME TAXES

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities. Deferred tax assets and unused tax losses have not been recognized in respect of the following deductible temporary differences:

| As at December 31, | 2020 | 2019 |
|--|-----------------------|------------------|
| Capital loss carry-forward | \$ 31,975,443 | \$ 21,964,545 |
| Portfolio investments | - | 11,883,076 |
| Share issue costs | 4,173 | 6,260 |
| Property, plant and equipment | 53,054 | - |
| Others | 180,244 | 179,480 |
| | \$ 32,212,914 | \$ 34,033,361 |
| The following table summarizes the components of deferred tax: | | |
| As at December 31, | 2020 | 2019 |
| As at December 31, Deferred Tax Assets | 2020 | 2019 |
| , | \$ 2020 181,954 | \$ 2019 |
| Deferred Tax Assets | \$ | \$ 2019 - |
| Deferred Tax Assets Capital losses carried forward | \$ | 2019 - - |

The net capital loss carry forward may be carried forward indefinitely but can only be used to reduce capital gains. Share issue and financing costs will be fully amortized in 2022. The remaining deductible temporary differences may be carried forward indefinitely. Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the group can utilize the benefits therefrom.

Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

14. INCOME TAXES (continued)

The provision for income taxes differs from the result that would have been obtained by applying the combined federal and provincial statutory Canadian income tax rates of 26.5% (2019 - 26.5%) to the income (loss) before income taxes. The difference results from the following items:

FOUNTAIN ASSET

| For the years ended December 31, | 2020 | 2019 |
|---|-----------------|--------------------|
| Income before income taxes | \$ 2,576,612 | \$ (18,475,736) |
| Expected income tax recovery at statutory rates | \$ 682,802 | \$ (4,896,070) |
| Increase (decrease) resulting from: | | |
| Stock based compensation | 40,927 | - |
| Realized (gain) loss on portfolio investments | 1,199,674 | - |
| Unrealized (gain) loss on portfolio investments | (1,460,995) | - |
| Accounting gain on incentive plan settlement | (209,151) | - |
| Other permanent adjustments | (9,116) | 2,505,130 |
| Change in tax benefits not recognized | (244,141) | 2,420,315 |
| | \$ - | \$ 29,375 |
| The details of the provision for income taxes are as follows: | | |
| For the years ended December 31, | 2020 | 2019 |
| Current tax provision | \$ - | \$ 29,375 |
| Deferred tax provision | \$ - | \$ - |

15. MANAGEMENT OF FINANCIAL RISK AND SENSITIVITY ANALYSIS

The primary goals of the Company's risk management programs are to ensure that the outcomes of activities involving elements of risk are consistent with the Company's objectives and risk tolerance. The Company's investment strategy requires a level of risk in exchange for an above average return on investment. The Company plans to maintain an appropriate risk and reward balance while protecting the Company's financial operations from events that have the potential to materially impair its financial strength. Balancing risk and reward is achieved through aligning risk tolerance with the Company's business strategy, diversifying risk, pricing appropriately for risk, mitigating risk through preventative controls and transferring risk to third parties.

The success of the Company is dependent upon its ability to assess and manage all forms of risk that affect its operations. The Company is exposed to many factors that could adversely affect its business, financial conditions or operating results. Developing policies and procedures to identify risk and the implementation of appropriate risk management policies and procedures is the responsibility of senior management and the Board of Directors. The Board directly, or through its committees, reviews and approves these policies and procedures, and monitors their compliance with them through ongoing reporting requirements.

The investment operations of the Company's business involve the purchase and sale of securities and, accordingly, the majority of the Company's assets are currently comprised of financial instruments. The use of financial instruments can expose the Company to several risks, including liquidity, market, interest, credit and currency risks. A discussion of the Company's use of financial instruments and their associated risks is provided below. There has been no change to the Company's risk management policies or processes during the period.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

15. MANAGEMENT OF FINANCIAL RISK AND SENSITIVITY ANALYSIS (continued)

(a) Liquidity risk

Liquidity risk is the risk that the Company will have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital markets is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company, or if the value of the Company's investments declines, resulting in losses upon disposition. The Company generates cash flow primarily from its operational activities and the proceeds from the disposition of its investments, in addition to interest and dividend income earned on its investments. The Company has sufficient investments which are freely tradable and relatively liquid to fund its obligations as they become due under normal operating conditions. The Company's accounts payable, accrued liabilities and due to broker, all have contractual maturities of less than 30 days and are subject to normal trade terms. The syndicated loans carry similar terms and conditions and have various terms ranging from 9 to 30 months. Management is not aware of any trends or expected fluctuations that would create any liquidity deficiencies.

The Company believes that cash flow from continuing operations and existing cash resources will be sufficient to meet the Company's short-term requirements, as well as ongoing operations, and will be able to generate sufficient capital to support the Company's operations in the long-term. However, the Company may procure debt or equity financing from time to time to fund its operations.

(b) Market risk

The Company is exposed to certain market risk that the value of, or future cash flows from, the Company's financial assets will significantly fluctuate due to changes in market prices. The value of the financial assets can be affected by changes in interest rates, foreign exchange rates, and equity and commodity prices. The Company is exposed to market risk in trading its investments, and unfavorable market conditions could result in dispositions of investments at less than favorable prices. Additionally, the Company is required to mark to market its fair value through profit or loss investments at the end of each reporting period. This process could result in significant write-downs of the Company's investments over one or more reporting periods, particularly during periods of overall market instability, which would have a significant unfavorable effect on the Company's financial position. The Company manages market risk by having a portfolio which is not singularly exposed to any one issuer or class of issuers. The Board monitors changes in the market on an ongoing basis and adjusts the Company's lending and investing practices and policies when necessary to reduce the impact of the above risks.

The Company's investments include publicly-listed entities that are listed on a Canadian stock exchange. Changes in the fair value of investments designated as fair value through profit and loss are reported in the statement of comprehensive income.

The following table shows the estimated sensitivity on the statement of comprehensive income for the year ended December 31, 2020 from a change in closing price of the Company's publicly-listed investments, not including share purchase warrants and options (refer to note 8 for sensitivity of warrant and option inputs), of \$7,130,481 with all other variables held constant as at December 31, 2020:

| Percentage of change in closing prices | Change in comprehensive income (net of tax) from % increase in closing price | Change in comprehensive income (net of tax) from % decrease in closing price |
|---|--|--|
| 5% | \$ 356,524 | \$ (356,524) |
| 10% | \$ 713,048 | \$ (713,048) |



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

15. MANAGEMENT OF FINANCIAL RISK AND SENSITIVITY ANALYSIS (continued)

(c) Interest rate risk

The observable impacts on the fair values and future cash flows of financial instruments that can be directly attributable to interest rate risk include changes in net income from financial instruments whose cash flows are determined with reference to floating interest rates and changes in value of financial instruments whose cash flows are fixed in nature.

Should market interest rates rise, then the fair value of these convertible debentures and term debt may decrease. Conversely, should market interest rates fall, the fair value of these assets may increase. The effect of changes in interest rates on the fair value of these debt instruments is partially muted by the nature of the investments. Convertible debentures placed in early stage investees are typically less sensitive to changes in market interest rates than non-convertible debt instruments placed in more mature investees. Additionally, the economic exposure to interest rate risk is mitigated by the Company's intention to either convert the debentures into the related underlying equities or, in the case of nonconvertible debentures, to hold the instrument until maturity.

As at December 31, 2020, if interest rates were higher by 1% per annum, the potential effect to the Company would be an increase in net income of approximately \$11,501 (December 31, 2019 – \$69,668).

(d) Credit risk

Concentration of credit risk may arise from exposures to a single debtor or to a group of debtors having similar characteristics such that their ability to meet their current obligations is expected to be affected similarly by changes in economic or other conditions. Senior management is committed to several processes to ensure that this risk is appropriately mitigated. These include:

- obtaining collateral guarantees;
- the investigation of the creditworthiness of all borrowers;
- the engagement of qualified independent consultants such as lawyers and real estate appraisers, to whom management may reach for professional advice.
- the segregation of duties to ensure that qualified staff are satisfied with all due diligence requirements prior to funding; and
- the prompt initiation of recovery procedures on overdue loans.

As at December 31, 2020, gross accounts receivable of \$nil and \$263,411 of convertible loans and debentures were past due (December 31, 2019 - \$nil and \$nil of convertible loans and debentures).

| As at | December 31 2020 | , December 31, 2019 |
|--|---------------------------|------------------------|
| Amounts receivable Loans and convertible debentures | \$ 1,160,833 1,299,195 | |
| | \$ 2,460,028 | 8 \$ 3,592,887 |

(e) Currency risk

Foreign exchange risk exposures arise from transactions and balances denominated in foreign currencies. The Company's foreign currency risk arises primarily with respect to the United States dollar. Fluctuations in the exchange rates between the United States dollar and the Canadian dollar could have a material effect on the Company's business, financial condition and results of operations. The Company does not engage in any hedging activity to mitigate this risk.



Presented in Canadian Dollars

For the years ended December 31, 2020 and 2019

15. MANAGEMENT OF FINANCIAL RISK AND SENSITIVITY ANALYSIS (continued)

(e) Currency risk (continued)

The Company has cash and cash equivalents, certain receivables, convertible debentures and investments in companies denominated in a foreign currency. For the year ended December 31, 2020 management estimates that if the United States dollar had strengthened or weakened by 10% against the Canadian dollar, assuming all other variables remained constant, net income for the year would have increased or decreased by approximately \$427,302 (December 31, 2019 - \$609,021).

(f) Concentration risk

Included in Investments - FVTPL is one investment which comprises 10% of the balance (2019 - 12%).

16. CONTINGENCIES AND COMMITMENTS

The Company is the parent company of the general partner of GC Global Capital Lending Partners Limited Partnership and Somersby Park 2010 General Partner Inc. The General Partner has unlimited liability for the liabilities and obligations of the partnerships in excess of the contributions of the limited partners. As at December 31, 2020, there were no outstanding liabilities or obligations for which the Company was contingently liable.

On September 4, 2017, the Company announced that it was served with a statement of claim by First Global Data Limited ("**FGD**"). The claim seeks damages of \$20,000,000 against a number of defendants including the Company and its former Chief Executive Officer, alleging breach of contract, conspiracy and various other causes of action (the "**FGD Action**").

The Company believes the claim against the Company and its former CEO is without merit and frivolous, and has been commenced in an attempt to delay the outcome of the Company's claims against FGD in existing proceedings commenced by the Company on February 3, 2017 (Ontario Superior Court of Justice Court File No. CV-17-569015, the "**Application**"). The Company commenced the Application because FGD has refused to honour its contractual obligations to issue certain options and warrants to the Company.

As a result of an August 24, 2017 order of the Ontario Superior Court of Justice, the Company's Application will be pursued as a counterclaim in the FGD Action. The Company will vigorously defend the FGD Action and will vigorously pursue its claims against FGD. Specifically, the Company will seek damages of at least \$6,015,000, equal to the difference between the purchase price per share under the Options/Warrants, and the highest trading value to date, as well as punitive and exemplary damages of \$2,000,000. The counterclaim by the Company against FGD and others is difficult to precisely quantify as the Company's claim is in respect of the enforcement of rights under certain options and warrants, not only pure damages.

No amounts have been accrued in the financial statements with respect to this matter.